{"id":"https://openalex.org/W7164124635","doi":"https://doi.org/10.1212/wnl.0000000000215009","title":"Exposure-response (ER) and Clinical Trial Simulations for Efficacy of Ecopipam in Adults and Pediatrics with Tourette\u2019s Syndrome (TS) (P2-16.001)","display_name":"Exposure-response (ER) and Clinical Trial Simulations for Efficacy of Ecopipam in Adults and Pediatrics with Tourette\u2019s Syndrome (TS) (P2-16.001)","publication_year":2026,"publication_date":"2026-06-09","ids":{"openalex":"https://openalex.org/W7164124635","doi":"https://doi.org/10.1212/wnl.0000000000215009"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000215009","doi":"https://doi.org/10.1212/wnl.0000000000215009","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000215009","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082707084","display_name":"Stephen P. Wanaski","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen Wanaski","raw_affiliation_strings":["Paragon Biosciences, LLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paragon Biosciences, LLC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086365200","display_name":"Soha Freidy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Soha Freidy","raw_affiliation_strings":["Allucent"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allucent","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5138332234","display_name":"Patricia Rice","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patricia Rice","raw_affiliation_strings":["Emalex Biosciences, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emalex Biosciences, Inc","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015590542","display_name":"Timothy M. Cunniff","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Timothy Cunniff","raw_affiliation_strings":["Paragon Biosciences, LLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paragon Biosciences, LLC","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070117385","display_name":"Virginia D. Schmith","orcid":"https://orcid.org/0000-0003-2841-2384","observed_orcids":["https://orcid.org/0000-0003-2841-2384"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Virginia Schmith","raw_affiliation_strings":["Schmith PK/PD Consulting, LLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schmith PK/PD Consulting, LLC","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.4080924,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"106","issue":"11_Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11123","display_name":"Obsessive-Compulsive Spectrum Disorders","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11123","display_name":"Obsessive-Compulsive Spectrum Disorders","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ecopipam","display_name":"ecopipam","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tourette-syndrome","display_name":"Tourette syndrome","score":0.9739999771118164},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.9900000095367432},{"id":"https://openalex.org/keywords/clinical-trial-simulation","display_name":"clinical trial simulation","score":0.9039999842643738},{"id":"https://openalex.org/keywords/pediatric-patients","display_name":"pediatric patients","score":0.7149999737739563},{"id":"https://openalex.org/keywords/adults","display_name":"adults","score":0.7269999980926514},{"id":"https://openalex.org/keywords/efficacy","display_name":"efficacy","score":0.4950000047683716},{"id":"https://openalex.org/keywords/glutamatergic-agents","display_name":"glutamatergic agents","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8432999849319458},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.6886000037193298},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6554999947547913},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.36820000410079956},{"id":"https://openalex.org/C2992477034","wikidata":"https://www.wikidata.org/wiki/Q83042","display_name":"Clinical neurology","level":2,"score":0.2930999994277954},{"id":"https://openalex.org/C986699","wikidata":"https://www.wikidata.org/wiki/Q7939","display_name":"El Ni\u00f1o","level":2,"score":0.2777999937534332},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.2685000002384186},{"id":"https://openalex.org/C2779281540","wikidata":"https://www.wikidata.org/wiki/Q5062122","display_name":"Central nervous system disease","level":2,"score":0.23170000314712524},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.2222999930381775},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2215999960899353}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000215009","doi":"https://doi.org/10.1212/wnl.0000000000215009","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000215009","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4367303932","https://openalex.org/W7164206944","https://openalex.org/W4405836503","https://openalex.org/W2084534611","https://openalex.org/W7162422666","https://openalex.org/W4394600102","https://openalex.org/W2890157050","https://openalex.org/W4206780165","https://openalex.org/W4410303950","https://openalex.org/W7119036461"],"abstract_inverted_index":{"Objective":[0],"To":[1],"characterize":[2],"the":[3,29,83,103,133,164,237,248,287,292,313,415],"E-R":[4,109],"relationship":[5],"of":[6,31,51,106,209,212,239,250,289,294,315,333,363,377,391,417],"ecopipam":[7,58,262,295],"in":[8,33,144,163,271,296,342,350,398,405,414],"TS":[9],"patients,":[10,19],"to":[11,21,26,28,57,286],"identify":[12],"any":[13],"differences":[14,143],"between":[15],"adult":[16,272],"and":[17,20,67,73,95,123,139,148,227,257,273,281,298,309],"pediatric":[18,274],"perform":[22],"clinical":[23,96,104,282],"trial":[24,97,179,244,283],"simulations":[25,180,245,284],"add":[27,285],"weight":[30,288],"efficacy":[32,112,253,293],"adults":[34,299],"with":[35,61,276,300],"TS.":[36,52,277,301],"Background":[37],"Ecopipam":[38,53],"is":[39,54,263],"a":[40,62,158,185,203,207,241,422],"first-in-class":[41],"selective":[42],"dopamine-1":[43],"receptor":[44],"(D1R)":[45],"antagonist":[46],"being":[47,240],"investigated":[48],"for":[49,111,142,261,291,328,358,372,386,419,424],"treatment":[50],"primarily":[55],"metabolized":[56],"glucuronide":[59,69],"(E-G),":[60],"minor":[63],"metabolite,":[64],"EBS-101-40853":[65],"(EBS)":[66],"its":[68],"conjugate":[70],"(EBS-G).":[71],"EBS":[72],"E-G":[74],"are":[75],"also":[76],"active":[77,135,219],"but":[78],"much":[79],"less":[80],"potent":[81],"at":[82,175],"D1R":[84],"than":[85],"ecopipam.":[86,107],"Design/Methods":[87],"A":[88],"pre-specified":[89],"population":[90],"pharmacokinetics":[91],"(PopPK),":[92],"exposure-response":[93],"(E-R),":[94],"simulation":[98],"plan":[99],"was":[100,113,130,155,200,269],"utilized":[101],"throughout":[102],"development":[105],"An":[108],"model":[110],"developed":[114],"using":[115,152],"data":[116],"from":[117,161],"Phase":[118,124],"2b":[119],"study":[120,126,187,221],"EBS-101-CL-001":[121],"(RCT)":[122],"3":[125],"EBS-101-TD-301":[127],"(RWD).":[128],"Exposure":[129],"defined":[131,156,201],"as":[132,157,202,330,360,374,388,421],"combined":[134],"exposure":[136],"(ecopipam,":[137],"EBS,":[138],"E-G),":[140],"corrected":[141],"potency,":[145],"protein":[146],"binding,":[147],"brain":[149],"penetration":[150],"predicted":[151],"PopPK.":[153],"Response":[154],"\u226525%":[159],"improvement":[160],"baseline":[162],"Yale":[165],"Global":[166],"Tic":[167,172],"Severity":[168],"Scale":[169],"\u2013":[170],"Total":[171],"Score":[173],"(YGTSS-TTS)":[174],"Week":[176],"8.":[177],"Clinical":[178,243],"(n=500)":[181],"were":[182,233,304],"conducted":[183,270],"assuming":[184],"RCT":[186,224,268],"(50":[188],"adults/50":[189],"pediatrics":[190,196,297],"on":[191,197],"ecopipam,":[192],"50":[193,195],"adults/":[194],"placebo.":[198],"Success":[199],"p":[204],"<0.017":[205],"AND":[206],"probability":[208,238,249],"response":[210],"active-placebo":[211],"\u226515%,":[213],"\u226520%,":[214],"or":[215,225,318,339,347],"\u226525%.":[216],"Results":[217],"Combined":[218],"exposure,":[220],"type":[222],"(whether":[223],"RWD)":[226],"age":[228],"group":[229],"(<18,":[230],"\u226518":[231],"years)":[232],"important":[234],"covariates":[235],"describing":[236],"responder.":[242],"showed":[246],"that":[247],"successfully":[251],"demonstrating":[252],"(active-placebo":[254],"\u2265":[255,264],"20%)":[256],"clinically":[258],"meaningful":[259],"benefit":[260],"90%":[265],"if":[266],"an":[267,331,361,375,389],"patients":[275],"Conclusions":[278],"PopPK,":[279],"E-R,":[280],"evidence":[290],"Disclaimer:":[302],"Abstracts":[303],"not":[305,311],"reviewed":[306],"by":[307],"Neurology\u00ae":[308,316],"do":[310],"reflect":[312],"views":[314],"editors":[317],"staff":[319],".":[320],"Disclosure:":[321],"Dr.":[322,336,380,394,401,408],"Wanaski":[323,337,345],"has":[324,338,346,354,368,382,396,403,410],"received":[325,355,369,383,411],"personal":[326,356,370,384,412],"compensation":[327,357,371,385,413],"serving":[329,359,373,387,420],"employee":[332,362,376,390],"Paragon":[334,343,392],"Biosciences.":[335,379,393,400,407,426],"had":[340,348],"stock":[341,349,397,404],"Biosciences.Dr.":[344,352],"Emalex":[351,378,406,425],"Freidy":[353],"Allucent,":[364],"LLC.,.":[365],"Patricia":[366],"Rice":[367],"Cunniff":[381,395,402],"Harmony":[399],"Schmith":[409],"range":[416],"$100,000-$499,999":[418],"Consultant":[423]},"counts_by_year":[],"updated_date":"2026-10-26T11:51:55.731654","created_date":"2026-06-11T00:00:00"}